Other than ibrutinib, patients with M-CLL, devoid of TP53 aberrations and suit adequate to tolerate FCR therapy, should still be great candidates for the latter, with the benefit staying that this treatment is usually accomplished in 6 months even though ibrutinib should be taken indefinitely. This selection will be particularly https://eddieb567qnm6.wikififfi.com/user